Oral targeted therapy for the treatment of non-small cell lung carcinoma.
作者信息
Phillips William J, Leighl Natasha B, Blais Normand, Wheatley-Price Paul
机构信息
Department of Medicine (Phillips, Wheatley-Price), University of Ottawa, Ottawa, Ont.; Department of Medicine (Leighl), Princess Margaret Cancer Centre, University of Toronto, Toronto, Ont.; Department of Medicine (Blais), Centre hospitalier de l'Université de Montréal, University of Montreal, Montréal, Que.; the Ottawa Hospital Research Institute (Wheatley-Price), Ottawa, Ont.
出版信息
CMAJ. 2024 Apr 28;196(16):E558-E561. doi: 10.1503/cmaj.231562.
Abstract
摘要
相似文献
1
Oral targeted therapy for the treatment of non-small cell lung carcinoma.
CMAJ. 2024 Apr 28;196(16):E558-E561. doi: 10.1503/cmaj.231562.
2
Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
Ann Oncol. 2018 Jan 1;29(suppl_1):i1-i2. doi: 10.1093/annonc/mdx724.
3
[Molecular targeted therapies and cytotoxics: Friends or foes?].
Bull Cancer. 2015 Jun;102(6 Suppl 1):S91-2. doi: 10.1016/S0007-4551(15)31223-6.
4
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.
5
[Not Available].
Med Clin (Barc). 2016 Apr;146 Suppl 1:1. doi: 10.1016/S0025-7753(16)30255-X.
6
[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
Magy Onkol. 2012 Mar;56(1):38-49. Epub 2012 Jan 15.
7
Third-generation EGFR-TKIs—a new hope for NSCLC.
Lancet Respir Med. 2014 Jul;2(7):520. doi: 10.1016/s2213-2600(14)70095-5.
8
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.
9
Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
JAMA Oncol. 2015 Sep;1(6):838-40. doi: 10.1001/jamaoncol.2015.1300.
10
Targeted therapies for advanced non-small cell lung cancer.
Comb Chem High Throughput Screen. 2012 Sep;15(8):641-55. doi: 10.2174/138620712802650513.
引用本文的文献
1
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03195-7.
2
Nomogram prediction model for overall survival of late-stage lung cancer patients undergoing iodine-125 particle implantation brachytherapy.
J Contemp Brachytherapy. 2024 Dec;16(6):410-427. doi: 10.5114/jcb.2024.146836. Epub 2024 Dec 31.
3
MYST2 histone acetyltransferase promotes lung adenocarcinoma progression by regulating the p38 MAPK signaling pathway.
Transl Oncol. 2025 Jan;51:102218. doi: 10.1016/j.tranon.2024.102218. Epub 2024 Nov 27.
4
Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective.
Curr Oncol. 2024 Oct 8;31(10):6017-6031. doi: 10.3390/curroncol31100449.
本文引用的文献
1
Recent progress in targeted therapy for non-small cell lung cancer.
Front Pharmacol. 2023 Feb 21;14:1125547. doi: 10.3389/fphar.2023.1125547. eCollection 2023.
2
Selpercatinib in Patients With Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
J Clin Oncol. 2023 Jan 10;41(2):385-394. doi: 10.1200/JCO.22.00393. Epub 2022 Sep 19.
3
Projected estimates of cancer in Canada in 2022.
CMAJ. 2022 May 2;194(17):E601-E607. doi: 10.1503/cmaj.212097.
4
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Clin Cancer Res. 2022 Jun 1;28(11):2286-2296. doi: 10.1158/1078-0432.CCR-21-3530.
5
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
World J Clin Oncol. 2021 Apr 24;12(4):217-237. doi: 10.5306/wjco.v12.i4.217.
6
Patient-Reported and End-of-Life Outcomes Among Adults With Lung Cancer Receiving Targeted Therapy in a Clinical Trial of Early Integrated Palliative Care: A Secondary Analysis.
J Pain Symptom Manage. 2021 Sep;62(3):e65-e74. doi: 10.1016/j.jpainsymman.2021.02.010. Epub 2021 Feb 20.
7
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
8
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.
9
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
10
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
J Med Econ. 2018 Feb;21(2):192-200. doi: 10.1080/13696998.2017.1389744. Epub 2017 Oct 18.
Zotero 插件